A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06672575
- Locations
- ๐บ๐ธ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06670105
- Locations
- ๐บ๐ธ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Pilot Study of Management of Facial Paralysis in the Oncologic Patient: Nerve Transfer Techniques to Improve Facial Function and Quality of Life
- Conditions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06667427
- Locations
- ๐บ๐ธ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT06668584
- Locations
- ๐บ๐ธ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution As Pre-emptive Therapy in AML): a Multi-arm, Precision-based, Recursive, Platform Trial
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT06664879
- Locations
- ๐บ๐ธ
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT06660420
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
Symptom Burden and Health Related Quality of Life of Cancer Patients with Concurrent Heart Failure
- Conditions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT06656715
- Locations
- ๐บ๐ธ
The University of Texas of MD Anderson Cancer Center, Houston, Texas, United States
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
- Conditions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1600
- Registration Number
- NCT06651580
- Locations
- ๐บ๐ธ
Children's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธUniversity of Colorado, Denver, Colorado, United States
๐บ๐ธCedars Sinai Medical Center, Los Angeles, California, United States
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06651593
- Locations
- ๐บ๐ธ
Md Anderson Cancer Center, Houston, Texas, United States
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
- Conditions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 316
- Registration Number
- NCT06649058
- Locations
- ๐บ๐ธ
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States